Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DNA Stock Forecast 2026-2027
$8.29
Current Price
$587.92M
Market Cap
Buy 1
Hold 0
Sell 2
Wall St Analyst Ratings
Distance to DNA Price Targets
+44.8%
To High Target of $12.00
+2.5%
To Median Target of $8.50
-39.7%
To Low Target of $5.00
DNA Price Momentum
-8.8%
1 Week Change
-3.0%
1 Month Change
-15.1%
1 Year Change
-0.2%
Year-to-Date Change
-52.8%
From 52W High of $17.58
+54.4%
From 52W Low of $5.37
📊 TOP ANALYST CALLS
Did DNA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ginkgo Bioworks is one of their latest high-conviction picks.
Latest DNA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, DNA has a bearish consensus with a median price target of $8.50 (ranging from $5.00 to $12.00). The overall analyst rating is Hold (5.3/10). Currently trading at $8.29, the median forecast implies a 2.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 2 Sell ratings.
Conversely, the most conservative target is provided by Mark Massaro at BTIG, suggesting a 39.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DNA Analyst Ratings
1
Buy
0
Hold
2
Sell
DNA Price Target Range
Low
$5.00
Average
$8.50
High
$12.00
Current: $8.29
Latest DNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2026 | BTIG | Mark Massaro | Sell | Maintains | $5.00 |
| Jan 8, 2026 | TD Cowen | Buy | Maintains | $N/A | |
| Aug 25, 2025 | BTIG | Sell | Maintains | $N/A | |
| Sep 20, 2024 | TD Cowen | Buy | Maintains | $N/A | |
| Aug 23, 2024 | BTIG | Sell | Maintains | $N/A | |
| Jul 9, 2024 | Goldman Sachs | Sell | Maintains | $N/A | |
| Jun 26, 2024 | BTIG | Sell | Maintains | $N/A | |
| May 15, 2024 | BTIG | Sell | Downgrade | $N/A | |
| May 15, 2024 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| May 10, 2024 | William Blair | Underperform | Downgrade | $N/A | |
| Mar 1, 2024 | TD Cowen | Outperform | Maintains | $N/A | |
| Jan 23, 2024 | Goldman Sachs | Sell | Maintains | $N/A | |
| Jan 22, 2024 | Goldman Sachs | Sell | Maintains | $N/A | |
| Nov 15, 2023 | Raymond James | Market Perform | Downgrade | $N/A | |
| Nov 14, 2023 | Raymond James | Market Perform | Downgrade | $N/A | |
| Nov 9, 2023 | BTIG | Neutral | Downgrade | $N/A | |
| Jun 5, 2023 | Goldman Sachs | Sell | Maintains | $N/A | |
| Jun 2, 2023 | Goldman Sachs | Sell | Downgrade | $N/A | |
| May 11, 2023 | William Blair | Market Perform | Downgrade | $N/A | |
| Nov 29, 2022 | Berenberg | Buy | Initiates | $N/A |
Ginkgo Bioworks Holdings Inc. (DNA) Competitors
The following stocks are similar to Ginkgo Bioworks based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ginkgo Bioworks Holdings Inc. (DNA) Financial Data
Ginkgo Bioworks Holdings Inc. has a market capitalization of $587.92M with a P/E ratio of -1.6x. The company generates $151.40M in trailing twelve-month revenue with a -201.1% profit margin.
Revenue growth is -49.1% quarter-over-quarter, while maintaining an operating margin of -366.5% and return on equity of -56.0%.
Valuation Metrics
Market Cap
$587.92M
Enterprise Value
$625.16M
P/E Ratio
-1.6x
PEG Ratio
0.1x
Price/Sales
3.9x
Growth & Margins
Revenue Growth (YoY)
-49.1%
Gross Margin
+84.1%
Operating Margin
-366.5%
Net Margin
-201.1%
EPS Growth
-59.7%
Financial Health
Cash/Price Ratio
+69.0%
Current Ratio
5.2x
Debt/Equity
92.7x
ROE
-56.0%
ROA
-16.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ginkgo Bioworks Holdings Inc. (DNA) Business Model
About Ginkgo Bioworks Holdings Inc.
What They Do
Biotechnology platform for cell programming services.
Business Model
The company operates on a platform-based business model, providing a range of biological R&D services through its Cell Engineering and Biosecurity segments. It generates revenue by offering flexible, end-to-end solutions for engineered organisms and biomonitoring services, catering to various sectors including food, pharmaceuticals, and industrial chemicals.
Additional Information
Founded in 2008 and headquartered in Boston, Massachusetts, the company utilizes autonomous labs to automate research workflows, significantly enhancing efficiency in synthetic biology. Ginkgo Bioworks Holdings Inc. aims to revolutionize biotech innovation by enabling organizations to program biology much like software development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
485
CEO
Dr. Jason Kelly Ph.D.
Country
United States
IPO Year
2021
Website
www.ginkgo.bioGinkgo Bioworks Holdings Inc. (DNA) Latest News & Analysis
Latest News
Quick Summary
Ginkgo Bioworks (NYSE: DNA) launched ADME-One™, an integrated ADME platform for drug discovery, co-developed with Tangible Scientific and Inductive Bio, enhancing lead optimization efforts.
Why It Matters
The launch of ADME-One™ enhances drug discovery efficiency through advanced AI and integrated management, potentially leading to faster and more cost-effective development, positively impacting Ginkgo Bioworks' valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Ginkgo Bioworks: Another Lost Year
2 months ago
Quick Summary
Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% YoY, missing estimates. Q1 cash burn was $49M, with guidance for 2026 at $125M–$150M. The company has $373M cash and no debt.
Why It Matters
Ginkgo Bioworks’ significant revenue drop and lack of guidance raise concerns about its financial health, cash burn, and ability to pivot effectively, potentially impacting investor confidence and stock performance.
Source: Seeking Alpha
Market Sentiment:
Negative
Ginkgo Bioworks Q1 Earnings Call Highlights
2 months ago
Quick Summary
Ginkgo Bioworks (NYSE: DNA) is focusing on autonomous laboratories for 2026 after divesting its biosecurity business and reporting reduced cash burn in Q1.
Why It Matters
Ginkgo Bioworks is streamlining operations and reducing cash burn, which may improve financial stability and growth potential, making it more attractive to investors.
Source: MarketBeat
Market Sentiment:
Negative
Quick Summary
Ginkgo Bioworks Holdings, Inc. (DNA) held its Q1 2026 earnings call, providing updates on financial performance and strategic initiatives. Detailed results and insights may impact investor decisions.
Why It Matters
Ginkgo Bioworks' Q1 2026 earnings reveal financial health, growth prospects, and operational efficiency, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Ginkgo Bioworks reported its Q1 2026 financial results, post-divestiture of its Biosecurity business. Detailed information is available on their investor website.
Why It Matters
Ginkgo's first quarter results post-divestiture provide insights into its financial health and strategic direction, influencing investor sentiment and potential stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Ginkgo Bioworks will host a Q&A session on May 7, 2026, at 4:30 p.m. ET to discuss Q1 2026 business performance. Details will be available on their investor relations website.
Why It Matters
Ginkgo Bioworks' upcoming presentation will provide insights into Q1 2026 performance, potentially influencing stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DNA Stock
What is Ginkgo Bioworks Holdings Inc.'s (DNA) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Ginkgo Bioworks Holdings Inc. (DNA) has a median price target of $8.50. The highest price target is $12.00 and the lowest is $5.00.
Is DNA stock a good investment in 2027?
According to current analyst ratings, DNA has 1 Buy ratings, 0 Hold ratings, and 2 Sell ratings. The stock is currently trading at $8.29. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DNA stock?
Wall Street analysts predict DNA stock could reach $8.50 in the next 12 months. This represents a 2.5% increase from the current price of $8.29. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ginkgo Bioworks Holdings Inc.'s business model?
The company operates on a platform-based business model, providing a range of biological R&D services through its Cell Engineering and Biosecurity segments. It generates revenue by offering flexible, end-to-end solutions for engineered organisms and biomonitoring services, catering to various sectors including food, pharmaceuticals, and industrial chemicals.
What is the highest forecasted price for DNA Ginkgo Bioworks Holdings Inc.?
The highest price target for DNA is $12.00 from at , which represents a 44.8% increase from the current price of $8.29.
What is the lowest forecasted price for DNA Ginkgo Bioworks Holdings Inc.?
The lowest price target for DNA is $5.00 from Mark Massaro at BTIG, which represents a -39.7% decrease from the current price of $8.29.
What is the overall DNA consensus from analysts for Ginkgo Bioworks Holdings Inc.?
The overall analyst consensus for DNA is bearish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 2 as Sell, with a median price target of $8.50.
How accurate are DNA stock price projections?
Stock price projections, including those for Ginkgo Bioworks Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:25 AM UTC